---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-008680"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T21:52:28.368495+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics launches AI program ADMAlytics, automates plasma pooling in first commercial batch

## Summary
- ADMAlytics combines generative AI and machine learning to optimize production processes.
- First successful commercial use: automated plasma pooling for ASCENIV production.
- Broader implementation across supply chain and operations expected to yield efficiencies.
- CEO Adam Grossman says ADMAlytics supports earnings growth trajectory and continuity of patient care.

## SEC filing metadata
- accession: 0001140361-24-008680
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036124008680/0001140361-24-008680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036124008680/ef20022054_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-008680
- JSON: https://secwatch.observer/filing/0001140361-24-008680.json
- Plain text: https://secwatch.observer/filing/0001140361-24-008680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.